Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence

Fabio Conforti^{1

2}, Federico Merlo³, Laura Pala^{1

2}, Jacopo Canzian¹, Benedetta Tinterri¹, Tommaso De Pas¹, Marzia Locatelli², James C Dickerson⁴, Javier Cortes^{5

6

7

8

9

10}, Dennis J Slamon¹¹, Richard Gelber¹², Vincenzo Bagnardi³

Affiliations

¹ Humanitas University, Milan, Italy.
² Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy.
³ Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
⁴ Division of Oncology, Stanford University School of Medicine, Stanford, CA.
⁵ International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
⁶ IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain.
⁷ Oncology Department, Hospital Universitario Torrejón, Ribera Group, Madrid, Spain.
⁸ Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.
⁹ Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
¹⁰ Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ.
¹¹ David Geffen School of Medicine at UCLA, Los Angeles, CA.
¹² Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation, Boston, MA.

Fabio Conforti et al. J Clin Oncol. 2025.

. 2025 Oct 20;43(30):3237-3244.

doi: 10.1200/JCO-25-01148. Epub 2025 Sep 17.

¹ Humanitas University, Milan, Italy.
² Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy.
³ Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
⁴ Division of Oncology, Stanford University School of Medicine, Stanford, CA.
⁵ International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
⁶ IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain.
⁷ Oncology Department, Hospital Universitario Torrejón, Ribera Group, Madrid, Spain.
⁸ Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.
⁹ Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
¹⁰ Medica Scientia Innovation Research (MEDSIR), Ridgewood, NJ.
¹¹ David Geffen School of Medicine at UCLA, Los Angeles, CA.
¹² Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation, Boston, MA.

No abstract available

LinkOut - more resources